Fujifilm Pays $2 Billion to Establish U.S. Cell-Culture Manufacturing Plant

Fujifilm is investing $2 billion in a high-output U.S. cell-culture manufacturing plant to speed the expansion of its biopharmaceutical contract development and manufacturing organization business.

Scheduled to be operational in 2025, the facility will produce antibodies, recombinant proteins, gene therapies and vaccines, and it will have automated fill-finish and assembly, packing and labeling capabilities.

In June 2020, Fujifilm announced a $928 million investment in Diosynth Biotechnologies’ Danish site to double its cell-culture output there.